Aerpio Pharmaceuticals Inc. (ARPO)’s Financial Results Comparing With Motif Bio plc (NASDAQ:MTFB)

This is therefore a comparing of the institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation in Aerpio Pharmaceuticals Inc. (NASDAQ:ARPO) and Motif Bio plc (NASDAQ:MTFB). The two are both Biotechnology companies that compete with one another.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aerpio Pharmaceuticals Inc. 1 0.00 24.85M -0.36 0.00
Motif Bio plc 1 0.00 14.76M -1.44 0.00

In table 1 we can see Aerpio Pharmaceuticals Inc. and Motif Bio plc’s top-line revenue, earnings per share and valuation.


Table 2 has Aerpio Pharmaceuticals Inc. and Motif Bio plc’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
Aerpio Pharmaceuticals Inc. 3,598,841,419.26% -20.5% -17.7%
Motif Bio plc 2,378,343,538.51% 0% 0%

Insider and Institutional Ownership

Institutional investors owned 23.4% of Aerpio Pharmaceuticals Inc. shares and 6.46% of Motif Bio plc shares. About 1.1% of Aerpio Pharmaceuticals Inc.’s share are owned by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Aerpio Pharmaceuticals Inc. 0.13% -8.73% -22.06% -79.51% -80.37% -53.24%
Motif Bio plc -2.36% -5.74% -72.7% -93.75% -92.68% -90.47%

For the past year Aerpio Pharmaceuticals Inc.’s stock price has smaller decline than Motif Bio plc.


On 7 of the 9 factors Aerpio Pharmaceuticals Inc. beats Motif Bio plc.

Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for ocular diseases. The company's lead product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a single ascending dose clinical trial for the treatment of inflammatory bowel disease. The company is headquartered in Cincinnati, Ohio. Aerpio Pharmaceuticals, Inc.(OTCPK:ARPO) operates independently of Akebia Therapeutics, Inc. as of December 22, 2011.

Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis. Motif Bio plc was incorporated in 2014 and is based in New York, New York.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.